Literature DB >> 8957023

Onset of dementia is associated with apolipoprotein E epsilon4 in Down's syndrome.

N Schupf1, D Kapell, J H Lee, W Zigman, B Canto, B Tycko, R Mayeux.   

Abstract

We examined the influence of apolipoprotein E (apoE) genotype on risk of dementia in 82 adults with Down's syndrome (DS). Compared with those with an apoE 3/3 genotype, the group of adults with DS with apoE 2/4, 3/4, and 4/4 genotypes were 5 times more likely to become demented (RR = 4.7; 95% CI = 1.2, 17.9). We hypothesize that the increased risk of dementia may be mediated by exacerbation of beta-amyloid deposition.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8957023     DOI： 10.1002/ana.410400518

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  24 in total

1.  Links between the pathology of Alzheimer's disease and vascular dementia.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; Yong-sheng Li; David Quartermain; Karen Duff; Thomas Wisniewski
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

2.  Estrogen receptor-alpha variants increase risk of Alzheimer's disease in women with Down syndrome.

Authors:  Nicole Schupf; Joseph H Lee; Michelle Wei; Deborah Pang; Constance Chace; Rong Cheng; Warren B Zigman; Benjamin Tycko; Wayne Silverman
Journal:  Dement Geriatr Cogn Disord       Date:  2008-04-14       Impact factor: 2.959

3.  Alzheimer's Disease in Adults with Down Syndrome.

Authors:  Warren B Zigman; Darlynne A Devenny; Sharon J Krinsky-McHale; Edmund C Jenkins; Tiina K Urv; Jerzy Wegiel; Nicole Schupf; Wayne Silverman
Journal:  Int Rev Res Ment Retard       Date:  2008-01-01

4.  Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial.

Authors:  Mary Sano; Paul S Aisen; Howard F Andrews; Wei-Yann Tsai; Florence Lai; Arthur J Dalton
Journal:  Neurology       Date:  2016-05-04       Impact factor: 9.910

Review 5.  Improving Memory and Cognition in Individuals with Down Syndrome.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

6.  Alzheimer-Related Cerebrovascular Disease in Down Syndrome.

Authors:  Patrick J Lao; José Gutierrez; David Keator; Batool Rizvi; Arit Banerjee; Kay C Igwe; Krystal K Laing; Mithra Sathishkumar; Fahmida Moni; Howard Andrews; Sharon Krinsky-McHale; Elizabeth Head; Joseph H Lee; Florence Lai; Michael A Yassa; H Diana Rosas; Wayne Silverman; Ira T Lott; Nicole Schupf; Adam M Brickman
Journal:  Ann Neurol       Date:  2020-10-09       Impact factor: 10.422

Review 7.  Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome.

Authors:  Xu-Qiao Chen; Mariko Sawa; William C Mobley
Journal:  Free Radic Biol Med       Date:  2017-10-12       Impact factor: 7.376

8.  Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.

Authors:  Elizabeth Head; Eric Doran; Mihaela Nistor; MaryAnn Hill; Frederick A Schmitt; Richard J Haier; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

9.  Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.

Authors:  V P Prasher; S G Sajith; P Mehta; W B Zigman; N Schupf
Journal:  Int J Geriatr Psychiatry       Date:  2010-02       Impact factor: 3.485

10.  Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome.

Authors:  Joseph H Lee; Maruit Chulikavit; Deborah Pang; Warren B Zigman; Wayne Silverman; Nicole Schupf
Journal:  Neurosci Lett       Date:  2007-08-25       Impact factor: 3.046
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.